A lot of people turn to weight loss drugs hoping for a quick, effective way to improve their health. Shedding pounds fast sounds great until the side effects kick in. Drugs like Ozempic, Wegovy, Mounjaro, and Saxenda have been linked to serious problems, like stomach paralysis, gallbladder issues, and long-term digestive trouble. What started as hope for better health turned into hospital stays, missed work, painful procedures, and a lot of unanswered questions. Week after week, more patients come forward with nearly identical horror stories.
If this describes your experience, trust this: your concerns are valid and shared by thousands. A mounting legal response is exposing the true dangers of these medications and the questionable marketing practices behind them. Victims nationwide are uniting to demand justice by joining the ongoing weight loss drug lawsuit efforts.
This article breaks down the latest on weight loss drug lawsuits, from the current Mounjaro lawsuit update today to the broader receptor agonist class action. We’ll cover major claims like the leading Rybelsus claim, updates on the Ozempic class action lawsuit, and what’s happening with Saxenda, Wegovy, and similar drugs. If you’re trying to understand your legal options, this guide will give you the essential information you need to understand your rights and next steps.
As of April 2026, lawsuits tied to popular weight loss drugs have grown to more than 3,500 cases in the U.S. Most of them are now being handled together in two multi district litigations in Pennsylvania, overseen by Judge Karen S. Marston.
MDL 3094 (Stomach and digestive injuries): This is the largest group, with about 3,363 cases. These lawsuits involve serious stomach problems like gastroparesis (slow or paralyzed stomach), ileus, and bowel blockages.
MDL 3163 (Vision loss): This smaller group has about 73 cases. These claims involve sudden, permanent vision loss linked to a condition called NAION.
No nationwide settlement has been reached yet with Novo Nordisk or Eli Lilly.
Litigation Developments
Let’s face it, changing what you eat and how you live is hard. That’s exactly why so many people look to weight loss medications for help. These prescriptions work by dialing down your hunger and making cravings more manageable. When you’re not fighting constant hunger pangs, eating less just happens naturally. And that’s how the pounds start coming off: by consistently taking in fewer calories than you burn.
The numbers tell the story: Americans spend about $2.1 billion annually on weight loss supplements, according to the National Institutes of Health. And roughly 15% of U.S. adults have tried them, usage is nearly twice as high among women (21%) compared to men (10%). The FDA has approved several of these medications, but their popularity doesn’t mean they’re right for everyone.
Today, weight loss drugs, especially newer GLP-1 receptor agonists, have become valuable tools for managing obesity. While they offer more effective and safer options than older medications, they’re not magic pills. Doctors stress that these drugs should only be used under careful medical supervision, balancing potential benefits against risks.
One thing remains clear: No medication replaces healthy habits. The 2025 Dietary Guidelines for Americans reaffirm that lasting weight loss still hinges on lifestyle changes, like nutritious eating, calorie awareness, and regular activity. Supplements and medications are just one piece of a much bigger picture.
Weight loss meds help in a few main ways:
Each one works a little differently, but the idea is the same: help you eat less and burn more. That said, they’re not meant to replace good habits. They work best when you’re also eating better and staying active. These meds are a boost, not a fix-all.
These meds aren’t for everyone. They’re usually for adults who’ve tried to lose weight through eating better and moving more but haven’t gotten the results they need.
Most of the time, doctors prescribe them if:
Some of those health issues might include:
In some cases, people with rare genetic causes of obesity might also qualify. These drugs can make a real difference but they’re part of a bigger plan, not a quick fix.
Here’s a rundown of the weight loss meds that have full FDA approval for long-term use. These aren’t just appetite suppressants. They each work in different ways to help with weight management, and they’re all approved for specific age groups and health conditions:
These meds aren’t one-size-fits-all, and they’re not meant to replace healthy habits. But they can be a powerful part of a bigger plan for people who qualify.
Some medications originally designed for type 2 diabetes are now commonly used for weight loss, either off-label or at higher doses that are FDA-approved for managing weight. Many of these work by slowing down digestion, reducing hunger, or helping your body lose extra calories through urine.
Here’s a breakdown of the main ones:
Weight loss usually ranges from about 3 to 5 pounds over 6 months.
A Few Quick Notes
Just like with weight loss–specific meds, lifestyle changes still matter. These drugs work best when combined with better eating habits and regular activity. And if you stop taking them, weight often creeps back.
Most people using weight loss drugs while making lifestyle changes lose between 5-10% of their body weight. In medical terms, it’s enough to make a real difference in health outcomes.
Some of the newer options are changing expectations though. Take Zepbound (tirzepatide). In clinical trials, many patients saw 15% or greater weight reduction after a full year. But here’s the thing no one tells you upfront: your results will depend on which medication you’re prescribed, the dosage that works for you, and how your body responds.
These drugs work best when you’re also putting in the work with better food choices and regular movement. And there’s another hard reality: if you stop taking them, the weight often comes back. That’s because obesity isn’t a temporary condition; it’s something most people need to manage long-term.
The good news? Even that 5-10% weight loss doctors talk about can lead to noticeable improvements: Better blood pressure numbers, improved blood sugar control, and healthier cholesterol levels. At the end of the day, these medications are tools, helpful for many, but not instant solutions. The most successful patients use them as part of a complete approach to health.
Here’s a quick look at the weight loss meds people are actually using in 2025. Some are household names by now, thanks to their popularity on social media and growing demand across the country.
These medications don’t all work the same way, but they’re some of the most widely prescribed and talked-about options for weight management right now. Some are designed specifically for weight loss, while others started as diabetes treatments and later got the green light for weight-related use.
What does semaglutide vs GLP-1 drugs mean? Semaglutide is one medication in a wider group called GLP-1 receptor agonists. These drugs all work by acting like a natural hormone that helps control blood sugar, slow digestion, and reduce appetite, which is why they’re used for diabetes and weight loss. Semaglutide, found in Ozempic and Wegovy, lasts longer in the body, so it’s usually taken once a week. Other GLP-1 drugs like liraglutide are taken daily. Some studies show semaglutide may offer slightly stronger results in blood sugar control and weight loss.
Like anything else in healthcare, weight loss drugs come with both upsides and downsides. Knowing both can help you make a more informed decision.
Pros:
Cons:
Medications like Ozempic, Wegovy, Mounjaro, Rybelsus, and Saxenda are everywhere right now when it comes to weight loss. But here’s the thing, only Wegovy and Saxenda are actually FDA-approved for weight management. The rest are technically diabetes meds, though doctors often prescribe them for weight loss too. Regardless of how they’re used, these GLP-1 drugs share many of the same potential side effects, and it’s important to understand what you might be signing up for. Let’s break it down, from the more common side effects to the rare but serious risks.
These meds tend to affect the digestive system the most, but they can also impact other parts of the body. Here are some general categories of side effects seen across the board:
For popular weight loss drugs:
Mild effects:
These symptoms usually show up as your dose increases but tend to fade with time.
Serious risks:
Common complaints:
More serious side effects:
Typical side effects:
Serious side effects:
Milder side effects:
More severe reactions:
Most common side effects:
These usually show up early and often improve with time.
More serious risks:
It’s important to weigh the benefits against the risks and talk with a healthcare provider about what makes sense for your body and your health goals. Informed choices matter.
Drugs like Ozempic, Wegovy, Saxenda, Mounjaro, Rybelsus, and Trulicity have seen a sharp rise in use over the past few years. Originally designed to help manage type 2 diabetes, these medications are now widely used for weight loss as well. But while many people have found success with these drugs, others have experienced serious side effects, and lawsuits are following.
A growing number of people are taking legal action, claiming these medications caused significant harm and that the drugmakers didn’t do enough to warn users about the risks. These lawsuits have been grouped into a multidistrict litigation (MDL). The MDL titled In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation (MDL No. 3094) is centralized in the Eastern District of Pennsylvania. This allows the courts to handle similar claims together instead of separately, making the process more efficient.
The lawsuits center on GLP-1 receptor agonist medications made by:
Most of the claims argue that the manufacturers failed to give patients and doctors proper warnings about the potential risks. Some of the most serious complications reported include:
Many people say they would have chosen a different treatment, or at least been more closely monitored, if they had known about these risks upfront.
Some of the key legal questions in the MDL include:
You may be eligible to file a claim, depending on your state’s statute of limitations, if you:
As of mid-2025, more than 1,800 lawsuits are active in the MDL. The legal process is moving forward, with discovery and expert reviews underway. The drug manufacturers are defending their products, and no major settlements have been reached yet. However, Ozempic attorneys are still reviewing new cases and encouraging those who’ve been affected to explore their legal options.
As of April 2026, the GLP-1 weight loss drug litigation (MDL No. 3094) has grown quickly, with over 3,400 cases involving gastrointestinal injuries, along with a related MDL (No. 3163) for vision loss (NAION), up from 1,800 cases in May 2025. The court is managing the process through a series of structured deadlines and hearings designed to keep things moving efficiently while both sides build their cases.
Here’s a look at some of the major developments, both recent and upcoming, in the MDL:
In the background of these formal steps, plaintiffs are pushing back against attempts by the defense to limit the scope of the lawsuits. While the drug companies argue that failure-to-warn claims are the only valid ones, plaintiffs are also alleging fraud and defective design.
The court has held regular status conferences to keep things on track and is overseeing ongoing procedures like Plaintiff Fact Sheets and electronic filings. A “Science Day” has either been held or is on the calendar, where both sides present information about how these drugs might be causing injuries like gastroparesis.
Wegovy, Novo Nordisk’s weight loss drug, is facing a wave of lawsuits claiming the company didn’t properly warn users about serious side effects. These cases are now part of MDL No. 3094 in federal court in Philadelphia.
Users of Wegovy have reported severe health problems, especially:
Beyond digestive issues, lawsuits also link Wegovy to vision loss, blood clots, certain cancers, and neurological problems like ALS.
The core legal claims in Wegovy lawsuits are:
Though no official settlements are set yet, estimates suggest compensation could range from $400,000 to $700,000 for serious injuries. Each case depends on the facts and severity of harm.
Ozempic lawsuits are part of MDL No. 3094. They accuse Novo Nordisk and Eli Lilly of not warning users about serious side effects from semaglutide, the main ingredient in Ozempic.
People taking Ozempic have reported serious health problems like:
The core legal allegations in Ozempic lawsuits are:
The main question in a lawsuit against Ozempic is whether Novo Nordisk failed to properly warn users and misled them through its marketing. Plaintiffs want compensation for medical bills, pain, and other damages.
A key May 14, 2025, Rule 702 hearing reviewed whether expert testimony linking Ozempic to injuries like gastroparesis could be used in court. In August 2025, Judge Marston ruled that claims must be supported by objective medical testing, such as gastric emptying studies or other diagnostic tests, and dismissed design defect claims while allowing failure-to-warn and some marketing claims to continue. Defendants continue to push for dismissal in cases without strong medical evidence. Fact discovery closed in July 2025, expert discovery finished in March 2026, and summary judgment motions are ongoing as of April 2026. The court has also limited broader marketing discovery to focus on labeling issues, while short-form complaints continue to streamline new filings in MDL 3094, which now includes over 3,500 cases. No global settlement has been reached, and significant payouts are not expected before late 2026.
Saxenda lawsuits say Novo Nordisk didn’t properly warn patients and doctors about serious side effects from the drug. Saxenda is used for weight loss in adults and teens with obesity or a high BMI.
The legal claims in the GLP 1 lawsuits are:
Over 1,100 Saxenda lawsuits are now part of MDL No. 3094, alongside Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1 cases, bringing the total to more than 3,500 claims. As of April 2026, the litigation has moved past fact discovery (July 2025) and expert discovery (March 2026), and the court has already held the May 14, 2025, Rule 702 hearing requiring objective diagnostic testing to support injury claims. The case is now in summary judgment motions and bellwether selection, with trials expected in mid-2026.
No global settlement or trial verdicts have been reached yet. Some severe, well-documented cases have projected values of $400,000 to $700,000, but outcomes will depend on future rulings and trial results.
People are suing Eli Lilly over Mounjaro, a drug for diabetes and weight loss, saying it caused serious and sometimes lasting health problems. The main issue is that Eli Lilly didn’t properly warn patients and doctors about these risks.
Here’s what the Eli Lilly lawsuits say:
What’s happening now:
The cases are still in early stages, with important hearings coming in 2025 to decide how strong the science is linking Mounjaro to these injuries and if the warnings were good enough. Courts are looking closely at how gastroparesis is diagnosed and if the FDA-approved labels were enough. The first Mounjaro lawsuit about stomach paralysis was filed in August 2023.
Common side effects mentioned include:
As of April 2026, hundreds of Mounjaro (tirzepatide) cases remain active within MDL No. 3094, which now totals about 3,546 lawsuits across GLP-1 drugs. The litigation is now in the pretrial phase, with summary judgment motions and bellwether case selection underway after the close of fact discovery in July 2025 and expert discovery in March 2026. No settlements have been reached, and the outcome will largely depend on how early bellwether trials play out.
Rybelsus, a type 2 diabetes drug often used off-label for weight loss, is now at the center of growing lawsuits. People are saying the drug caused serious health problems, and that Novo Nordisk didn’t do enough to warn about them.
The Novo Nordisk lawsuits are saying:
In addition to gastrointestinal issues, there are separate lawsuits just for eye-related injuries like blindness linked to Rybelsus.
No settlements have been reached yet. Some sources suggest future payouts could range from $100,000 to $1 million, depending on the injuries, but that’s still speculative at this point.
If you’ve been hurt by a weight loss drug, it’s important to know what steps to take if you’re thinking about legal action. Here’s a quick breakdown of the process:
If you or a loved one suffered serious health issues after taking a weight loss drug like Ozempic, Wegovy, Rybelsus, Trulicity, or Mounjaro, you may qualify for a lawsuit. At Ethen Ostroff Law, we’re reviewing cases where people experienced severe side effects tied to these drugs.
Here’s what we look for in cases we accept:
You must have taken one of these medications:
You must have:
We’re currently taking cases involving any of these serious complications, either while taking the medication or within a few months of stopping:
If your experience matches any of these, reach out. These cases are time-sensitive, and it’s important to take action as soon as possible.
Victims of weight loss drug injuries have the option to join a GLP-1RA class action lawsuit rather than pursue an individual Wegovy and Ozempic lawsuit. Class action lawsuits involve a group of individuals who have suffered similar injuries due to the same product, such as a weight loss drug. Consider whether joining a class action is the right choice for you with the help of your attorney.
Benefits of joining a class action lawsuit include:
There’s a deadline for taking legal action after you’ve been harmed by a weight loss drug. It’s called the statute of limitations, and it varies depending on where you live. In Pennsylvania, the statute of limitations for product liability and personal injury claims is two years from the date of injury or the date the injury was discovered or reasonably should have been discovered.
You could lose the chance to file a claim and recover compensation if you miss that deadline. It’s important to talk to a lawyer as soon as you suspect something is wrong. They’ll help you figure out how much time you have and make sure everything gets filed on time.
For individuals harmed by medications like Ozempic or Mounjaro, successful legal claims may recover several types of damages:
The specific compensation available depends entirely on your individual circumstances. An experienced semaglutide attorney or liraglutide attorney can help pursue the fullest possible recovery.
Taking on a pharmaceutical company isn’t easy, especially when you’re dealing with serious health issues at the same time. These cases often involve complex medical records, expert testimony, and corporate legal teams that don’t make things simple.
That’s exactly why EOL.Law is here. Here’s how we will support you throughout your case:
Reach out to us today for a free consultation and find out if you qualify.
Yes, you could sue if you got hurt by Ozempic, Wegovy, Mounjaro, or Zepbound. You need proof you took the drug and medical records of stomach paralysis, bowel blockage, or vision loss. Most cases are grouped together in one big lawsuit. You can get compensation for medical bills and missed work.
You qualify if you took name-brand Ozempic for at least 30 days and got gastroparesis, ileus, or vision loss. You need medical records that prove your injury started while on the drug or right after stopping. You do not qualify if you are over 75, had stomach surgery before, or took compounded versions. Talk to a lawyer to check your case.
People are suing because Novo Nordisk did not warn that Ozempic could cause stomach paralysis and bowel blockages. The drug slows digestion, but the label only mentioned nausea, not permanent damage. Studies also show a link to sudden vision loss. Thousands of cases are now in court.
Same reason as above. Patients say the company hid the real risks of severe stomach injuries. The FDA also said Novo Nordisk did a bad job reporting bad reactions, including deaths. Lawsuits ask for compensation to cover hospital bills and suffering.
You need your prescription records showing you took name-brand Ozempic for at least 30 days. You also need test results like stomach-emptying scans, CTs, or eye exams that prove your injury. Hospital records and medical bills show what it costs you. A lawyer can help gather everything.
You need a lawyer because these cases are complicated, and drug companies have big legal teams. A lawyer gets your medical records, meets filing deadlines, and proves the drug caused your injury. Most lawyers work for free upfront and only get paid if you win. You will likely get more compensation with a lawyer than without one.
Saxenda is another weight loss drug made by the same company as Ozempic. Lawsuits say it caused stomach paralysis, bowel blockages, and gallbladder problems without proper warnings. These cases were added to the same group lawsuit as Ozempic in late 2024. People want compensation for medical bills and long-term health issues.
People complain about bad nausea, vomiting, constipation, and stomach pain from Zepbound. Lawsuits say Eli Lilly did not warn about serious risks like stomach paralysis, kidney injury, and vision loss. Over 3,300 cases, including Zepbound, are now in federal court. Many users say side effects do not go away even after stopping the drug.
His career began in public service as a Surveillance Officer in Maricopa County, where he gained firsthand experience in high-stakes decision-making and developed a deep sense of discipline and accountability. He later served as Chief Operating Officer of a fast-growing law firm, driving efficiency, revenue growth, and team development. Today, Ryan focuses on helping law firms reach their full potential by aligning people, processes, and long-term vision. A strategic thinker and empowering leader, Ryan is passionate about developing others and guiding organizations through meaningful, lasting growth.
Effective Date: July 10, 2024
General Information
Welcome to the website of Ethen Ostroff Law, PLLC (“EO”). By accessing or using our website, you agree to be bound by these Terms and Conditions (“Terms”). If you do not agree with these Terms, please do not use our website.
Use
EO hereby grants you a non-exclusive, non-transferable, revocable, limited right and license to access and use the Site solely for your personal use in accordance with these Terms of Use. You shall not, in any way, otherwise copy, reproduce, distribute, transmit, display, perform, reproduce, publish, license, modify, create derivative works from, sell, or exploit the Site.
EO may at any time, for any reason, and without notice or liability: (a) modify, suspend, or terminate operation of or access to the Site and related services, or (b) change, revise, or modify the Site and affiliated services.
Messaging and Automated Calls
When you opt-in, you will receive text messages (SMS/MMS) on your mobile number. These messages may contain information about your case, and the message frequency may vary from user to user. Please note that message and data rates may apply. If you wish to opt out of this service, you can do so anytime by simply texting “STOP” to the phone number. Once you text “STOP” to us, we will send you an SMS to confirm that you have been unsubscribed. If you encounter any issues, you can reply with the keyword “HELP” to get assistance. Please be aware that carriers are not responsible for any delayed or undelivered messages.
By providing your phone number and submitting a form on our website, you consent to receive communications, including automated calls, texts, and pre-recorded messages, from EO and its affiliates. These communications may include updates about your case, promotional offers, and other information. You understand that these calls may be generated using automated technology, and that standard message and data rates may apply.
Your consent to receive automated calls is not a condition of any purchase or service. By checking the consent box on our contact form or by calling our firm, you agree to these Terms and Conditions and provide your written consent to receive these communications. You may opt out of these communications at any time by replying STOP to any text message or by contacting us at [insert contact information].
State-Specific Compliance
EO complies with all federal and state laws regarding automated calls and telemarketing practices. Certain states have additional restrictions on the use of automated dialing systems and pre-recorded messages. The following states have more restrictive regulations:
If you are a resident of one of these states, EO will obtain your prior express written consent before making any automated calls or sending pre-recorded messages to you.
By submitting a form inquiry or calling our firm, you agree to us contacting you, and your checking the box when submitting your form inquiry serves as written consent.
Information and Legal Disclaimer
The information contained in this website is for informational purposes only, and should not be construed as legal advice. Testimonials and case results contained in this website are for demonstrative purposes only, and do not constitute a guarantee of any particular outcome in a specific case.
By requesting a free consultation with Ethen Ostroff Law, PLLC, you agree to the following:
The law differs in every jurisdiction, and you should not rely on any opinion except that of an attorney you have retained, who has a professional duty to advise you after being fully informed of all the pertinent facts, and who is licensed in the applicable state, and is familiar with the applicable law. Internet subscribers, mobile application users, and online readers should seek professional counsel about their legal rights and remedies. You should not act or refrain from acting on the basis of any information found on the Site. Any actions or decisions about your legal rights should be based on the particular facts and circumstances of your situation, and appropriate legal advice from an attorney retained directly by you. EO EXPRESSLY DISCLAIMS ALL LIABILITY WITH RESPECT TO ACTIONS TAKEN OR NOT TAKEN BASED UPON ANY INFORMATION OR OTHER CONTENTS OF THIS SITE. Viewing the Site, or communicating with EO by Internet e-mail or through the Site does not constitute or create an attorney-client relationship with anyone. The content and features on the Site do not create, and are not intended to create, an attorney-client relationship, and shall not be construed as legal advice. The content and features of the Site, including means to submit a question or information, do not constitute an offer to represent you or otherwise give rise to an attorney/client relationship.
THE SITE IS PROVIDED “AS IS”. EO MAKES NO WARRANTIES, EXPRESS OR IMPLIED, REGARDING THE SITE AND ONLINE SERVICES AND HEREBY DISCLAIMS ALL WARRANTIES OF ANY KIND OR NATURE, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, AND NON-INFRINGEMENT. WITHOUT LIMITING THE FOREGOING, EO DOES NOT GUARANTEE THAT THE ONLINE SERVICES OR PRODUCTS WILL MEET YOUR REQUIREMENTS, OR WILL BE ERROR-FREE, UNINTERRUPTED, OR FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS, OR THAT ANY DEFECTS WILL BE CORRECTED.
Accounts
To use some features of the Site, you may be required to create an account. In connection therewith, you agree to provide and maintain true, accurate, current, and complete information about yourself. You are responsible for maintaining the confidentiality of the information you hold for your account login, including your password, and for all Submissions made from your account. You agree to notify us immediately of any unauthorized use of your login. EO may suspend access to your account if it suspects illegal or improper use, or for other reasons, such as for account management purposes, at its sole discretion.
Confidentiality is Not Guaranteed
Information sent to Ethen Ostroff Law, PLLC. via Internet e-mail or through the Site is not secure and is done on a non-confidential basis. EO may make reasonable efforts to keep communications private, but because of the nature of Internet communications and the absence of an attorney/client relationship, we cannot promise or guarantee confidentiality.
DISCLAIMER – This Site Does Not Provide Medical Diagnosis or Advice
The content provided on the Site, such as documents, text, graphics, images, videos, news alerts, pharmaceutical drug recalls, prescription medication history, or information on litigation concerning the foregoing topics, or other materials, is for informational purposes only. The information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always consult a physician for diagnosis and treatment of any medical condition or for any questions you may have regarding a health concern. Never disregard professional medical advice, alter a prescription plan in any way, or delay or refrain from seeking medical advice because of something you have read or seen on the Site. Links to other sites are provided for information only. Use of trade names is for identification only and does not constitute endorsement by EO.
Without limiting the generality of the foregoing, the Site may present information about pharmaceutical drug recalls, which is for information purposes only. Such information is not necessarily the most current information on the subject and may or may not be updated based on the last information concerning such recalls. Do not make any decisions regarding medication or medical providers based on information from the Site, including but not limited to information we provide about drug recalls.
EO Is Not Responsible for Content; Limitation on Liability
EO may periodically change, remove, or add the material on the Site without notice. This material may contain technical or typographical errors. EO DOES NOT GUARANTEE ITS ACCURACY, COMPLETENESS OR SUITABILITY. EO assumes no liability or responsibility for any errors or omissions in the contents of the Site. Your use of the Site is at your own risk. Under no circumstances shall EO or any other party involved in the creation, production, or delivery of the Site be liable to you or any other person for any indirect, special, incidental, or consequential damages of any kind arising from your access to, or use of, the Site. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW IN NO EVENT SHALL EO BE LIABLE FOR ANY SPECIAL, INDIRECT, OR CONSEQUENTIAL DAMAGES RELATING TO THIS MATERIAL, FOR ANY USE OF THIS WEBSITE, OR FOR ANY OTHER LINKED WEBSITE.
Third-party Web Sites
The Site contains links to third-party websites for the convenience of our users. EO does not endorse any of these third-party sites and does not imply any association between EO and those sites. EO does not control these third-party websites and cannot represent that their policies and practices will be consistent with these Terms of Use. If you use links to access and use such websites, you do so at your own risk. EO is not responsible for the contents or availability of any linked sites. These links are provided only as a convenience to the recipient. These Terms only apply to the Site and do not apply to any linked sites. We encourage you to read and understand the terms of use of any linked sites that you visit. Links do not imply that we sponsor, endorse, are affiliated with or associated with, or are legally authorized to use any trademark, trade name, service mark, design, logo, symbol, or other copyrighted materials displayed on or accessible through any linked site.
EO Clients
Only individuals who have entered into a mutually signed retainer agreement with EO are EO clients (“EO Clients”).
Legal and Ethical Requirements
EO has tried to comply with all legal and ethical requirements in compiling the Site. We welcome comments about our compliance with the applicable rules and will update the Site as warranted, upon learning of any new or different requirements.
Ethen Ostroff Law reserves the right to refer or sell leads that come through any of Ethen Ostroff Law’s marketing.
Ethen Ostroff Law also may sell leads on certain campaigns generated in association with third party marketing companies.
Governing Laws in Case of Dispute; Jurisdiction
These Terms of Use shall be governed by and construed in accordance with the laws of the State of Pennsylvania, USA, without regard to any choice of law principles. Any and all disputes arising hereunder shall be governed as set forth in the Arbitration section below.
Submissions
You are solely responsible for any information, content, or material you transmit to or through the Site (“Submissions”). You understand that Submissions are considered non-confidential and non-proprietary. Furthermore, you grant EO an unrestricted, irrevocable, perpetual, transferable, sublicensable, worldwide, royalty-free license to use, copy, reproduce, display, publish, publicly perform, transmit, and distribute any Submission, without compensation or accounting to you or anyone else. You represent and warrant that: (a) you have the right to submit the Submission to EO and grant the licenses as described above; (b) EO will not need to obtain licenses from any third party or pay royalties to any third party for its use of the Submission; (c) the Submission does not infringe any third party’s rights, including intellectual property rights and privacy rights; and (d) the Submission complies with these Terms of Use and all applicable laws and regulations.
EO takes no responsibility and assumes no liability for any Submission.
Arbitration
Any and all claims by you arising out of or related to the Site or your use thereof may be resolved only through a binding arbitration proceeding to be conducted under the auspices of the Commercial Arbitration Rules of the American Arbitration Association in Montgomery County, Pennsylvania. Both your agreement to arbitrate all controversies, disputes and claims, and the results and awards rendered through the arbitration, will be final and binding on you and may be specifically enforced by legal proceedings. Arbitration will be the sole means of resolving such controversies, disputes and claims, and you waive your rights to resolve such controversies, disputes and claims by court proceedings or any other means. You agree that judgment may be entered on the award in any court of competent jurisdiction and, therefore, any award rendered shall be binding. The arbitrator may not consolidate more than one person’s claims, and may not otherwise preside over any form of a representative or class proceeding. You understand that by agreeing to arbitration as a mechanism to resolve all controversies, disputes and claims between us, you are waiving certain rights, including the right to bring an action in court, the right to a jury trial, the right to broad discovery, and the right to an appeal. You understand that in the context of arbitration, a case is decided by an arbitrator (one or more), not by a judge or a jury.
International Use
The Site is controlled, operated, and administered by EO from offices within the United States of America and is only intended for use therein. We make no representation regarding use of the Site outside of the United States.
Other Terms
If, for any reason, our Terms of Use, Privacy Policy, or any portion thereof to be unenforceable, such provision shall be enforced to the maximum extent permissible so as to give the intended effect thereof, and the remainder of these Terms of Use and Privacy Policy shall continue in full force and effect. EO’s failure to act with respect to a breach by you or others does not waive our right to act with respect to that breach or subsequent or similar breaches. No consent or waiver by EO hereof will be deemed effective unless in writing. These Terms of Use, together with our Privacy Policy, as each is currently posted, constitute the entire agreement between EO and you with respect to your use of the Site and supersede all previous written or oral agreements relating to the subject matter hereof, that this agreement shall not supersede, restrict, or replace any agreements governing the attorney-client relationship between EO and EO Clients.
EO may, in its sole discretion and without prior notice, block and/or terminate your access to the Site and if we determine that you have violated these Terms of Use or other terms or agreements or that may be associated therewith or if you use the Site in a way that we deem, in our sole discretion, to be an unacceptable use.
